Summary Safety Review - ZOFRAN (ondansetron) - Assessing the Potential Harm to the Fetus

Health Canada carried out a safety review to assess the risk of birth defects with the use of ondansetron, as part of routine health product monitoring and because this drug is not authorized for sale in Canada to treat nausea and vomiting during pregnancy. The use of ondansetron during pregnancy is not recommended because its safety has not been established in pregnant women.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Résumé de l'examen de l'innocuité – ZOFRAN (Ondansétron) – Évaluation du risque potentiel d'effets néfastes sur le fœtus
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2017-05-18 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Examen sommaire de l'innocuité", "ZOFRAN", "ondansétron", "évaluation", "effets nocifs potentiels pour le fœtus"], "en": ["Summary Safety Review", "ZOFRAN", "ondansetron", "assessing", "potential harm-to-the-Fetus"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source